Immunocore Holdings plc
IMCR
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.8B
$36.13
▼ -3.83%
P/E
150.54
Mkt Cap
$1.8B
52-Wk Range
$27.56–$40.72
52-Week Range
$27.56 - $40.72
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 1.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Profitability at risk
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+30.0% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IMCR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.02 vs -$0.01 consensus (-100.0% surprise). Revenue of $115.9M vs $148.6M expected (-22.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-100.0%
Revenue trend · last 2Q
—
+18%
Q1 26
Q2 26
$106.7M
$115.9M
Margins · last 2Q
Gross
99.1%
Operating
-2.6%
Profit
-0.7%
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Apr 20, 2026
vs Industry
How IMCR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.